Efficacy and Tolerance of Vascular Electrical Stimulation Therapy in the Management of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase II Single-Centre Randomized Study in Ivory Coast
Table 2
Severe and total vaso-occlusive crisis elimination time by age, sex, VAS admission score, disease phenotype, haematology, and treatment arm.
Parameters
Severe crisis elimination time (time to VAS ≤ 2), h
Total crisis elimination time (time to VAS = 0), h
Age, years
15–25
6.5 (2.5–15)
0.4526 NS
25–35
4 (3–8)
>35
14 (7–20)
Sex
Male
3.5 (2.5–12.5)
0.2894 NS
Female
8 (3–16)
VAS at admission
6–9
3 (1.5–8)
0.0110 S
30 (16–42)
0.2938 NS
10
10 (5–20)
18 (10–24)
Phenotype
SSFA2
9 (5–20)
0.4199 NS
20 (18–47)
0.6304 NS
SFA2
3 (1–14)
8 (5–48)
SC
4.5 (3–9)
20 (10–30)
SAFA2
20 (20–20)
30 (30–30)
CRP, mg/L
≤12
5.5 (2.5–9)
0.1511 NS
20 (14–30)
0.8598 NS
>12
15 (3–30)
24 (8–47)
Haemoglobin, g/dL
<8
8 (3–20)
0.7443 NS
20 (10–30)
0.9359 NS
8–10
8 (3–14)
30 (6–48)
>10
4.5 (3–10)
30 (30–30)
White blood cell count, cells/mm3
<10000
2.5 (1.25–8.5)
0.2985 NS
25 (12–54)
0.5833 NS
10000–15000
8 (3–20)
19 (3–33)
>15000
6 (3–8)
30 (30–30)
Treatment arm
Group 0
17 (8–54)
0.0374 S
33 (30–66)
0.0052 S
Group 1
3.5 (3–8)
19 (10–20)
Group 2
4 (1.5–10)
13 (5–20)
CRP, C-reactive protein; h, hours; NS, not significant; VAS, visual analogue score; , value with significance set at less than 0.05. Bold values imply the difference observed is statistically significant.
